{"id":15575,"date":"2025-04-29T06:00:00","date_gmt":"2025-04-29T06:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/"},"modified":"2025-04-29T06:00:00","modified_gmt":"2025-04-29T06:00:00","slug":"xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/","title":{"rendered":"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>12-m\u00e5nadersuppf\u00f6ljningen fr\u00e5n XVIVOs europeiska multicenterstudie f\u00f6r hj\u00e4rttransplantation, NIHP2019, har presenterats p\u00e5 kongressen International Society of Heart and Lung Transplantation 2024 (ISHLT) i Boston, USA. Studien syftade till att unders\u00f6ka transplantationsresultaten vid anv\u00e4ndning XVIVO Heart Assist Transport.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Analysen av l\u00e5ngtidsresultatet av NIHP2019-studien utv\u00e4rderade patientutfall 12 m\u00e5nader efter transplantation. Resultaten visade att allvarliga komplikationer uppstod hos 33 procent av patienterna som fick donerade hj\u00e4rtan bevarade med XVIVO Heart Assist Transport, j\u00e4mf\u00f6rt med 47 procent i kontrollgruppen, d\u00e4r donerade hj\u00e4rtan f\u00f6rvarades p\u00e5 is. Detta motsvarar en riskreduktion p\u00e5 38 procent. Analysen visade \u00e4ven att \u00f6verlevnaden efter 12-m\u00e5nader var h\u00f6gre bland patienterna i XVVO-gruppen: 92\u202fprocent, j\u00e4mf\u00f6rt med 86\u202fprocent i kontrollgruppen.<\/p>\n<p>XVIVOs hj\u00e4rtteknologi, vilken best\u00e5r av en XVIVO Heart Assist Transport-enhet och perfusionsl\u00f6sning, erbjuder ett alternativ till statisk kall bevaring med is. Enheten pumpar den syresatta perfusionsl\u00f6sningen, specifikt anpassad f\u00f6r detta \u00e4ndam\u00e5l, genom organet med ett l\u00e5gt tryck vid 8 grader Celsius. Detta bevarar hj\u00e4rtat i ett kontrollerat vilotillst\u00e5nd under l\u00e5g metabolism. Denna metod, som tidigare har visat sig framg\u00e5ngsrik vid lever- och njurtransplantationer, kallas f\u00f6r hypothermic oxygenated perfusion (HOPE).<\/p>\n<p>\u201dResultaten vid 12 m\u00e5nader bekr\u00e4ftar betydelsen av de resultat som tidigare rapporterades 30 dagar efter transplantation, d\u00e5 den kraftiga minskningen av allvarlig prim\u00e4r hj\u00e4rtdysfunktion (PGD) vi s\u00e5g d\u00e5 nu \u00e5terspeglas i minskat sjukdomstillst\u00e5nd och d\u00f6dlighet vid en l\u00e4ngre uppf\u00f6ljning\u201d, s\u00e4ger Filip Rega, Professor of Cardiac Surgery and Transplantation vid The University Hospitals Leuven, Belgium, som ocks\u00e5 \u00e4r studiens samordnande pr\u00f6vare. Han forts\u00e4tter, \u201dstudieresultaten visar p\u00e5 en viktig och kliniskt relevant minskning av allvarliga komplikationer efter transplantation f\u00f6r de patienter som transplanterats med ett donerat hj\u00e4rta som har bevarats med denna nya teknologi. Eftersom denna teknologi kan f\u00f6rl\u00e4nga den tid ett donerat hj\u00e4rta kan bevaras s\u00e4kert utanf\u00f6r kroppen s\u00e5 har vi nu en l\u00f6sning som kan reducera den h\u00e5rda tidspress som de strikta tidsbegr\u00e4nsningarna inneb\u00e4r f\u00f6r b\u00e5de preservation och transplantation av hj\u00e4rtan.\u201d<\/p>\n<p>\u201dDetta \u00e4r den f\u00f6rsta randomiserade, kontrollerade studien av en perfusionsteknologi f\u00f6r donerade hj\u00e4rtan som p\u00e5visar en stark f\u00f6rdel j\u00e4mf\u00f6rt med bevarande p\u00e5 is. Nu n\u00e4r det \u00e4r bevisat att den tidigare rapporterade 76-procentiga riskreduktionen f\u00f6r allvarlig PGD ocks\u00e5 \u00e5terspeglas i en h\u00f6gre 12-m\u00e5naders\u00f6verlevnad k\u00e4nner vi en stor stolthet, samtidigt som det tar oss ett steg n\u00e4rmare v\u00e5r vision att \u201dingen ska d\u00f6 i v\u00e4ntan p\u00e5 ett nytt organ\u201d. Som ett forskningsdrivet och innovativt f\u00f6retag \u00e4r v\u00e5r hj\u00e4rtteknologi ett bevis p\u00e5 att XVIVO \u00e4r dedikerade till att f\u00f6r\u00e4ndra paradigmet inom hj\u00e4rtpreservation,&#034; s\u00e4ger Christoffer Rosenblad, VD f\u00f6r XVIVO.<\/p>\n<p>Den kliniska studien NIHP2019 \u00e4r en randomiserad, kontrollerad, \u00f6ppen, multicenter klinisk pr\u00f6vning av XVIVO Heart Assist Transport som syftar till att samla in data om s\u00e4kerhet och effektivitet som skall anv\u00e4ndas som underlag f\u00f6r en CE-m\u00e4rkning. Inom studien NIHP2019 har 204 patienter inkluderats fr\u00e5n 15 transplantationskliniker i 8 europeiska l\u00e4nder mellan november 2020 och maj 2023.<br \/>\u00a0<br \/>29 april, 2025<br \/>G\u00f6teborg<br \/>Christoffer Rosenblad, VD<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-fb9cf3b124f9\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr \/>\n<p>Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com<br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-da5f5ee9f867\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr \/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/1258b7f4-7dbb-4be4-973f-381e1eca9a5b\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston.pdf\" rel=\"noopener\" target=\"_blank\">XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>12-m\u00e5nadersuppf\u00f6ljningen fr\u00e5n XVIVOs europeiska multicenterstudie f\u00f6r hj\u00e4rttransplantation, NIHP2019, har presenterats p\u00e5 kongressen International Society of Heart and Lung Transplantation 2024&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-15575","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO\" \/>\n<meta property=\"og:description\" content=\"12-m\u00e5nadersuppf\u00f6ljningen fr\u00e5n XVIVOs europeiska multicenterstudie f\u00f6r hj\u00e4rttransplantation, NIHP2019, har presenterats p\u00e5 kongressen International Society of Heart and Lung Transplantation 2024...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\\\/\",\"name\":\"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2025-04-29T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO","og_description":"12-m\u00e5nadersuppf\u00f6ljningen fr\u00e5n XVIVOs europeiska multicenterstudie f\u00f6r hj\u00e4rttransplantation, NIHP2019, har presenterats p\u00e5 kongressen International Society of Heart and Lung Transplantation 2024...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/","name":"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2025-04-29T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-presenterar-12-manadersuppfoljning-fran-europeisk-multicenterstudie-inom-hjarttransplantation-vid-ishlt-i-boston\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO presenterar 12-m\u00e5nadersuppf\u00f6ljning fr\u00e5n europeisk multicenterstudie inom hj\u00e4rttransplantation vid ISHLT i Boston"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/15575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=15575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}